Andrew Hollman Meyer's Insider Trades & SAST Disclosures
Andrew Hollman Meyer's most recent trade in Janux Therapeutics Inc was a trade of 3,333 Common Stock done at an average price of $4.2 . Disclosure was reported to the exchange on May 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Andrew Hollman Meyer.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics Inc | Meyer Andrew Hollman | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 01 May 2025 | 3,333 | 85,472 | - | 4.2 | 14,032 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 3,333 | 87,332 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 31.95 per share. | 01 May 2025 | 2,933 | 82,539 | - | 31.9 | 93,703 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 32.60 per share. | 01 May 2025 | 400 | 82,139 | - | 32.6 | 13,041 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2025 | 3,334 | 90,665 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 21 Apr 2025 | 3,334 | 85,473 | - | 4.2 | 14,036 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 21 Apr 2025 | 3,334 | 82,139 | - | 30 | 100,020 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 3,334 | 93,999 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 03 Mar 2025 | 3,334 | 85,473 | - | 4.2 | 14,036 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 31.88 per share. | 03 Mar 2025 | 2,433 | 83,040 | - | 31.9 | 77,576 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 32.85 per share. | 03 Mar 2025 | 901 | 82,139 | - | 32.9 | 29,599 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 3,334 | 97,333 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 03 Feb 2025 | 3,334 | 85,473 | - | 4.2 | 14,036 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 42.08 per share. | 03 Feb 2025 | 2,418 | 83,055 | - | 42.1 | 101,739 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 42.77 per share. | 03 Feb 2025 | 816 | 82,239 | - | 42.8 | 34,901 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 43.60 per share. | 03 Feb 2025 | 100 | 82,139 | - | 43.6 | 4,360 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 63,000 | 63,000 | - | - | Stock option (right to buy) | |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 18,000 | 95,473 | - | 0 | Common Stock | |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 54.51 per share. | 02 Jan 2025 | 5,768 | 86,783 | - | 54.5 | 314,420 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 55.76 per share. | 02 Jan 2025 | 3,444 | 83,339 | - | 55.8 | 192,033 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 53.76 per share. | 02 Jan 2025 | 2,922 | 92,551 | - | 53.8 | 157,081 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 56.78 per share. | 02 Jan 2025 | 1,000 | 82,339 | - | 56.8 | 56,778 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 57.36 per share. | 02 Jan 2025 | 200 | 82,139 | - | 57.4 | 11,473 | Common Stock |
| Janux Therapeutics Inc | Hollman Meyer Andrew | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.24 per share. | 19 Dec 2024 | 9,880 | 77,472 | - | 20.2 | 199,971 | Common Stock |
| Janux Therapeutics Inc | Meyer Hollman Andrew | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2024 | 9,880 | 96,870 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Hollman Andrew Meyer | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2024 | 1 | 89,999 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 19 Dec 2024 | 1 | 77,473 | - | 14 | 14 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 45.96 per share. | 27 Sep 2024 | 50,000 | 67,592 | - | 46.0 | 2,297,755 | Common Stock |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2024 | 50,000 | 100,667 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.21 per share. | 27 Sep 2024 | 50,000 | 117,592 | - | 4.2 | 210,500 | Common Stock |
| Janux Therapeutics Inc | Meyer Hollman Andrew | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 105,000 | 105,000 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Janux Therapeutics Inc | Andrew Hollman Meyer | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 106,750 | 106,750 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges